颗粒和:寻找一个3D打印的胃耐药梅醇剂量,用于儿科的管理
Khadija Rouaz-El Hajoui1, Helena Herrada-Manchón2, David Rodríguez-González3
1Departamento de Farmacia, Tecnología Farmacéutica y Físico Química, Facultad de Farmacia y Ciencias de la Alimentación. Universidad de Barcelona. Avda. Joan XXIII, 27-31. 08028 Barcelona, Spain.
International journal of pharmaceutics
|August 3, 2023
概括
3D打印药用口香糖为儿科梅的输送提供了一个新的方法. 这项技术增强了胃抵抗,并确保了适当的药物释放,解决了对pH值敏感药物的挑战.
科学领域:
- 制药技术 制药技术 制药技术
- 药物输送系统 药物输送系统
- 3D打印应用 3D打印应用
背景情况:
- 3D打印使定制制药生产成为可能,特别是对于需要特定剂量或配方的儿科患者.
- 复合药房正在探索固体口服剂的替代方案,重点关注口服液体配方.
- 在口服配方中确保pH敏感活性药物成分 (API) 的质量和稳定性,如梅,是一项挑战.
研究的目的:
- 开发针对患者量身定制的药用口香糖,使用半固体挤出3D打印技术,用于儿科奥梅普拉.
- 为了比较3D打印的水凝与溶解的奥梅普拉的性能,而不是那些装有胃耐药的奥梅普拉颗粒的水凝.
- 为了评估开发的3D打印梅醇的胃抵抗和溶解特征.
主要方法:
- 采用半固体挤出3D打印技术,制造了含有奥梅普拉的水凝皮.
- 两种配方进行了比较:含有溶解奥梅普拉的水凝和含有胃耐药奥梅普拉颗粒的水凝.
- 用各种分析方法评估了胃抵抗和溶解概况.
主要成果:
- 这两种3D打印的口香糖配方都表现出适当的风湿学,可打印性,并符合内容和质量统一性的标准.
- 配方包括胃耐药的奥梅普拉颗粒表现出优越的胃耐药性和合适的药物释放特征.
- 该研究强调了测定方法在比较胃抵抗和溶解方面的重要性.
结论:
- 半固体挤出3D打印是一种有效的策略,用于开发用于儿科的创新的梅药物形式.
- 将肠膜涂层颗粒纳入3D打印的可的半固体剂量,可以增强胃抵抗力,控制药物释放.
- 这种3D打印方法为提供具有挑战性的儿科药物提供一个有希望的解决方案.
相关概念视频
01:18Drug Delivery: Enteral Route
505
The enteral drug administration involves three primary routes: oral, sublingual, and buccal. Oral ingestion is the most prevalent, safe, economical, and convenient method for drug administration. However, it has certain drawbacks, including limited absorption due to the drug's low water solubility or poor membrane permeability, possible emesis from GI mucosa irritation, destruction of drugs by digestive enzymes or low gastric pH, and irregular absorption along with food or other drugs.
505
01:26Peptic Ulcer Disease IV: Management
110
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
110
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
471
Peptic ulcers, often induced by H. pylori infections or NSAID usage, arise from disruptions in the delicate balance of gastric acid production. Peptic ulcers stem from heightened gastric acid levels due to H. pylori infections or NSAID use. The protective mucus layer diminishes in the presence of these factors, allowing gastric acid to erode the stomach lining and form ulcers.
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
471
01:24Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
558
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
558
01:20Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
500
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
500
01:18Routes of Drug Administration: Enteral
3.8K
Medications can be administered through the enteral route using liquids, capsules, or tablets.
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
Enteral administration involves drug administration via the mouth in two ways: orally or sublingually.
Unlike sublingually drugs, drugs that are taken orally pass through the gastrointestinal (GI) tract and get metabolized by the liver. Once metabolized, the drug is absorbed into the systemic circulation, reaching different body parts via the bloodstream. However, while passing through the stomach,...
3.8K